Header Navigation

Age-related macular degeneration (AMD) is a progressive retinal disease that occurs in older people and progressively impairs the vision of those affected. To improve the diagnosis and treatment of this disease, the research team led by Prof. Dr. Thomas Ach at the University Hospital Bonn has developed an experimental fundus camera with spectral analysis, which will enable better detection and monitoring of the disease in the future.

The Laboratory of Molecular Physiology of Somatic Sensation at the Max Delbrück Center, led by Gary Lewin, together with Entrepreneur-in-Residence Klaas Yperman, is advancing a novel therapeutic approach to treat neuropathic pain by targeting the mechanosensory protein STOML3. The project focuses on translating robust academic discoveries into a therapy that addresses the underlying mechanisms of aberrant touch sensation. By selectively modulating STOML3 activity, the approach aims to restore normal sensory function while avoiding the side effects associated with current analgesics.

The aim of the StrokeCap project is to close a central gap in preclinical stroke diagnostics. Strokes are among the most common causes of death and often result in permanent neurological impairments in survivors. Early initiation of therapy is crucial for treatment success, because “time is brain”.

The Puringe project aims to develop an innovative syringe-based system for precise and contamination-free injections, with an initial focus on intravitreal operative medication administration (IVOM). The core innovation is a flexible, impermeable membrane that physically separates the drug from the syringe at all times, thereby reliably preventing contamination by silicone oil or abrasion particles. At the same time, the Puringe functions as an integrated dosing aid, structurally eliminating overfilling and reducing the risk of overdosing and drug waste.

Personalized neoepitope-based immunotherapies are considered a promising approach for the targeted treatment of cancer. These therapies are based on tumour-specific neoepitopes which arise through somatic mutations, occurring exclusively in tumour tissue, and can be recognized as foreign by the immune system.

With the EKFS doctoral program “IMMUNE PILOT,” the Medical Faculty of the University of Bonn introduces medical students to the interface between immunology, neuroscience, and genetics at an early stage and specifically prepares young medical professionals with a passion for research for a career as a clinician scientist. In addition to intensive supervision, structured qualification, and international exchange opportunities, participants also gain access to an exceptionally strong research infrastructure.